-

- - -

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2021-001854-74-FR

Enrollment

Registered

2021-05-12

Start date

2021-07-28

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: ROPIVACAINE 7,5 mg/mL Product Code: N01BB09 Pharmaceutical Form: Solution for injection INN or Proposed INN: ROPIVACAINE CAS Number: 84057-95-4 Concentration unit: mg milligram(s) Concent

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 42 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 42

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
Main Objective: -;Secondary Objective: -;Primary end point(s): - ;Timepoint(s) of evaluation of this end point: -	—

Secondary

Measure	Time frame
Secondary end point(s): -;Timepoint(s) of evaluation of this end point: -	—

Countries

France

Contacts

Public ContactDélégation à la Recherche Clinique

CHU de Clermont-Ferrand

promo_interne_drci@chu-clermontferrand.fr043373754963

Outcome results